These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22486586)

  • 1. Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children?
    Fürst-Recktenwald S; Dörr HG; Quinkler M; Dötsch J; Stewart PM
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):159-68. PubMed ID: 22486586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD; Azevedo I; Monteiro R; Martins MJ
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
    Hollis G; Huber R
    Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
    Boyle CD; Kowalski TJ
    Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
    Ge R; Huang Y; Liang G; Li X
    Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM
    Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW; Stewart PM
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
    Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
    Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
    Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
    Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.